Analyst Ratings for Intellia Therapeutics (NTLA)
NTLA Rating Summary
NTLA Price Target Summary
- Highest: $107.00 (Chardan Capital Markets)
- Lowest: $24.00 (Baird)
- Average: $67.12
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$67.12 (+217%)
* Over Last 12-Mos
Rating Score: 7.9 / 10
Percentile Rank: 83%
Avg. $ Target:
$67.12 (+217%)
* Over Last 12-Mos
Rating Score: 7.9 / 10
Percentile Rank: 83%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/23/2024 | Goldman Sachs » Updated 2/26/2024 |
Salveen Richter | Downgrade | Neutral (Buy) |
32.00 (136.00) |
27.18 (21.17) |
-22.11% | Details |
| 2/15/2024 | Wolfe Research | Andy Chen | New Coverage | Peerperform (N/A) |
N/A (N/A) |
26.45 (21.17) |
-19.96% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
